[Form 4] Harmony Biosciences Holdings, Inc. Insider Trading Activity
Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), sold 21,573 shares of the company's common stock on 08/15/2025 under a Rule 10b5-1 trading plan. The transactions were executed at a weighted average price of $36.4983 per share, with individual sale prices ranging from $36.11 to $36.87. After these dispositions, the Form 4 reports 0 shares beneficially owned by the reporting person. The filing notes the sale was made pursuant to an established trading plan and offers to provide, upon request, the number of shares sold at each price within the disclosed range.
Sandip Kapadia, Chief Financial Officer di Harmony Biosciences Holdings, Inc. (HRMY), ha venduto 21.573 azioni ordinarie della societ脿 il 15/08/2025 nell'ambito di un piano di trading ai sensi della Rule 10b5-1. Le operazioni sono state eseguite a un prezzo medio ponderato di $36,4983 per azione, con prezzi unitari compresi tra $36,11 e $36,87. Dopo queste cessioni, il Modulo 4 segnala 0 azioni detenute a titolo beneficiario dalla persona che ha effettuato la comunicazione. La dichiarazione precisa che la vendita 猫 avvenuta in base a un piano di negoziazione preesistente e si offre di fornire, su richiesta, il numero di azioni vendute a ciascun prezzo all'interno dell'intervallo comunicato.
Sandip Kapadia, Director Financiero (CFO) de Harmony Biosciences Holdings, Inc. (HRMY), vendi贸 21.573 acciones ordinarias de la compa帽铆a el 15/08/2025 bajo un plan de negociaci贸n conforme a la Regla 10b5-1. Las transacciones se realizaron a un precio medio ponderado de $36,4983 por acci贸n, con precios individuales entre $36,11 y $36,87. Tras estas disposiciones, el Formulario 4 informa de 0 acciones pose铆das de forma beneficiaria por la persona informante. La presentaci贸n indica que la venta se efectu贸 conforme a un plan de negociaci贸n establecido y ofrece, a petici贸n, proporcionar el n煤mero de acciones vendidas a cada precio dentro del rango declarado.
Harmony Biosciences Holdings, Inc. (HRMY)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Sandip Kapadia電� 2025雲� 8鞗� 15鞚� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 須岇偓 氤错喌欤� 21,573欤茧ゼ 毵り皝頄堨姷雼堧嫟. 瓯半灅電� 欤茧嫻 臧�欷戫弶攴� 臧�瓴� $36.4983鞐� 觳搓舶霅橃棃鞙茧┌, 臧滊硠 毵る弰 臧�瓴╈潃 $36.11鞐愳劀 $36.87 靷澊鞓�鞀惦媹雼�. 頃措嫻 觳橂秳 鞚错泟, Form 4鞐愲姅 氤搓碃鞚� 氤挫湢 0欤�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 毵り皝鞚� 靷爠鞐� 靹れ爼霅� 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞚岇潉 氇呾嫓頃橂┌, 鞖旍箔 鞁� 瓿店皽霅� 氩旍渼 雮� 臧� 臧�瓴╇寑鞐愳劀 毵り皝霅� 欤检嫕 靾橂ゼ 鞝滉车頃橁矤雼り碃 氚濏瀳瓿� 鞛堨姷雼堧嫟.
Sandip Kapadia, directeur financier (CFO) de Harmony Biosciences Holdings, Inc. (HRMY), a vendu 21 573 actions ordinaires de la soci茅t茅 le 15/08/2025 dans le cadre d'un plan de n茅gociation conforme 脿 la Rule 10b5-1. Les op茅rations ont 茅t茅 ex茅cut茅es 脿 un prix moyen pond茅r茅 de 36,4983 $ par action, les prix individuels variant de 36,11 $ 脿 36,87 $. Apr猫s ces cessions, le Formulaire 4 d茅clare 0 action d茅tenue 脿 titre b茅n茅ficiaire par la personne d茅clarante. Le dossier pr茅cise que la vente a 茅t茅 r茅alis茅e en vertu d'un plan de n茅gociation 茅tabli et propose, sur demande, de fournir le nombre d'actions vendues 脿 chaque prix dans l'intervalle divulgu茅.
Sandip Kapadia, Chief Financial Officer von Harmony Biosciences Holdings, Inc. (HRMY), verkaufte am 15.08.2025 im Rahmen eines Rule-10b5-1-Handelsplans 21.573 Stammaktien des Unternehmens. Die Transaktionen wurden zu einem gewichteten Durchschnittspreis von $36,4983 je Aktie ausgef眉hrt, wobei die einzelnen Verkaufspreise zwischen $36,11 und $36,87 lagen. Nach diesen Ver盲u脽erungen meldet Formular 4 0 Aktien n眉tzlichen Eigentums der meldenden Person. Die Einreichung weist darauf hin, dass der Verkauf gem盲脽 eines bestehenden Handelsplans erfolgte, und bietet an, auf Anfrage die Anzahl der zu jedem Preis innerhalb der angegebenen Spanne verkauften Aktien mitzuteilen.
- None.
- None.
Insights
TL;DR: Routine officer sale under a 10b5-1 plan; transaction is transparent but provides limited insight into company fundamentals.
The sale of 21,573 shares at a weighted average of $36.4983 was executed pursuant to a Rule 10b5-1 plan, which indicates the trades were pre-planned rather than opportunistic. Because the reporting person now reports zero beneficial ownership, the transaction eliminates this insider's direct equity stake disclosed on Form 4. This disclosure is procedurally important for compliance and market transparency, but without additional context on total share count, company valuation, or concurrent insider activity, the sale alone provides limited signal about Harmony's operational performance or near-term prospects.
TL;DR: The trade follows an established trading plan and was properly disclosed, reflecting adherence to insider trading controls.
The filing clearly indicates use of a Rule 10b5-1 trading plan and includes the weighted average price and price range, which supports disclosure completeness. From a governance perspective, documenting that the trades were effected under a plan helps mitigate concerns about selective insider timing. The fact that the reporting officer now shows no beneficial ownership is notable for governance records but the form does not include information about any related policies or whether other holdings are indirect or held by affiliates.
Sandip Kapadia, Chief Financial Officer di Harmony Biosciences Holdings, Inc. (HRMY), ha venduto 21.573 azioni ordinarie della societ脿 il 15/08/2025 nell'ambito di un piano di trading ai sensi della Rule 10b5-1. Le operazioni sono state eseguite a un prezzo medio ponderato di $36,4983 per azione, con prezzi unitari compresi tra $36,11 e $36,87. Dopo queste cessioni, il Modulo 4 segnala 0 azioni detenute a titolo beneficiario dalla persona che ha effettuato la comunicazione. La dichiarazione precisa che la vendita 猫 avvenuta in base a un piano di negoziazione preesistente e si offre di fornire, su richiesta, il numero di azioni vendute a ciascun prezzo all'interno dell'intervallo comunicato.
Sandip Kapadia, Director Financiero (CFO) de Harmony Biosciences Holdings, Inc. (HRMY), vendi贸 21.573 acciones ordinarias de la compa帽铆a el 15/08/2025 bajo un plan de negociaci贸n conforme a la Regla 10b5-1. Las transacciones se realizaron a un precio medio ponderado de $36,4983 por acci贸n, con precios individuales entre $36,11 y $36,87. Tras estas disposiciones, el Formulario 4 informa de 0 acciones pose铆das de forma beneficiaria por la persona informante. La presentaci贸n indica que la venta se efectu贸 conforme a un plan de negociaci贸n establecido y ofrece, a petici贸n, proporcionar el n煤mero de acciones vendidas a cada precio dentro del rango declarado.
Harmony Biosciences Holdings, Inc. (HRMY)鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� Sandip Kapadia電� 2025雲� 8鞗� 15鞚� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 須岇偓 氤错喌欤� 21,573欤茧ゼ 毵り皝頄堨姷雼堧嫟. 瓯半灅電� 欤茧嫻 臧�欷戫弶攴� 臧�瓴� $36.4983鞐� 觳搓舶霅橃棃鞙茧┌, 臧滊硠 毵る弰 臧�瓴╈潃 $36.11鞐愳劀 $36.87 靷澊鞓�鞀惦媹雼�. 頃措嫻 觳橂秳 鞚错泟, Form 4鞐愲姅 氤搓碃鞚� 氤挫湢 0欤�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞝滌稖靹滊姅 毵り皝鞚� 靷爠鞐� 靹れ爼霅� 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞚岇潉 氇呾嫓頃橂┌, 鞖旍箔 鞁� 瓿店皽霅� 氩旍渼 雮� 臧� 臧�瓴╇寑鞐愳劀 毵り皝霅� 欤检嫕 靾橂ゼ 鞝滉车頃橁矤雼り碃 氚濏瀳瓿� 鞛堨姷雼堧嫟.
Sandip Kapadia, directeur financier (CFO) de Harmony Biosciences Holdings, Inc. (HRMY), a vendu 21 573 actions ordinaires de la soci茅t茅 le 15/08/2025 dans le cadre d'un plan de n茅gociation conforme 脿 la Rule 10b5-1. Les op茅rations ont 茅t茅 ex茅cut茅es 脿 un prix moyen pond茅r茅 de 36,4983 $ par action, les prix individuels variant de 36,11 $ 脿 36,87 $. Apr猫s ces cessions, le Formulaire 4 d茅clare 0 action d茅tenue 脿 titre b茅n茅ficiaire par la personne d茅clarante. Le dossier pr茅cise que la vente a 茅t茅 r茅alis茅e en vertu d'un plan de n茅gociation 茅tabli et propose, sur demande, de fournir le nombre d'actions vendues 脿 chaque prix dans l'intervalle divulgu茅.
Sandip Kapadia, Chief Financial Officer von Harmony Biosciences Holdings, Inc. (HRMY), verkaufte am 15.08.2025 im Rahmen eines Rule-10b5-1-Handelsplans 21.573 Stammaktien des Unternehmens. Die Transaktionen wurden zu einem gewichteten Durchschnittspreis von $36,4983 je Aktie ausgef眉hrt, wobei die einzelnen Verkaufspreise zwischen $36,11 und $36,87 lagen. Nach diesen Ver盲u脽erungen meldet Formular 4 0 Aktien n眉tzlichen Eigentums der meldenden Person. Die Einreichung weist darauf hin, dass der Verkauf gem盲脽 eines bestehenden Handelsplans erfolgte, und bietet an, auf Anfrage die Anzahl der zu jedem Preis innerhalb der angegebenen Spanne verkauften Aktien mitzuteilen.
